Vikrant Piprode

Dr. Vikrant Piprode

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
PMParmanand Malvi
Parmanand Malvi
VPVikrant Piprode
Vikrant Piprode
BCBal Krishna Chaube
Bal Krishna Chaube
SPSatish T. Pote
Satish T. Pote
MMMonika Mittal
Monika Mittal
MBManoj Kumar Bhat
Manoj Kumar Bhat

7 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSahil A. Mapkar
Sahil A. Mapkar
SBSarah A. Bliss
Sarah A. Bliss
ECEdgar E. Perez Carbajal
Edgar E. Perez Carbajal
SMSean H. Murray
Sean H. Murray
ZLZhiru Li
Zhiru Li
MWMichael N. Wosczyna
Michael N. Wosczyna
Cellular senescence is an irreversible state of cell cycle arrest with a complex role in tissue repair, aging, and disease. However, inconsistencies in identifying cellular senescence have led to varying conclusions about their functional significance. We developed a machine learning-based approach that uses nuclear morphometrics to identify senescent cells at single-cell resolution. By applying unsupervised clustering and dimensional reduction techniques, we built a robust pipeline that distinguishes senescent cells in cultured systems, freshly isolated cell populations, and tissue sections. Here we show that this method reveals dynamic, age-associated patterns of senescence in regenerating skeletal muscle and osteoarthritic articular cartilage. Our approach offers a broadly applicable strategy to map and quantify senescent cell states in diverse biological contexts, providing a means to readily assess how this cell fate contributes to tissue remodeling and degeneration across lifespan.

7 November 2024 in Targets
Verified
Journal Article
Open access
PDF file
SCsurbhi chouhan
surbhi chouhan
AKAnil Kumar
Anil Kumar
VPVikrant Piprode
Vikrant Piprode
ADAPARAJITA DASGUPTA
APARAJITA DASGUPTA
SSSarojini Singh
Sarojini Singh
AKAbdul Khalique
Abdul Khalique
RAPTOR (regulatory-associated protein of mTOR) is a pivotal component of the mammalian target of rapamycin complex 1 (mTORC1), playing a central role in regulating cell growth, metabolism and stress responses. As a scaffold protein, RAPTOR recruits key substrates such as eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) and ribosomal protein S6 kinase (S6K), facilitating their phosphorylation by mTORC1, which in turn drives protein synthesis, lipid metabolism and cellular proliferation. Its regulatory function becomes especially crucial under conditions of nutrient deprivation or stress, where it enhances the stability of the mTORC1 complex, allowing cells to adapt to fluctuating environmental cues. The hyperactivation of mTORC1, largely mediated by RAPTOR, is frequently observed in various cancers, contributing to uncontrolled cell proliferation and tumorigenesis. Moreover, RAPTOR’s modulation of immune responses and metabolic pathways extends its influence beyond oncogenesis, impacting inflammatory diseases and metabolic disorders. This review meticulously elucidates RAPTOR’s structure, post-translational modifications as well as its indispensable role within the mTORC1 complex, emphasizing its regulatory functions in cellular growth, metabolic adaptation, immune response and disease pathology including oncogenesis. Furthermore, it explores emergent therapeutic avenues targeting RAPTOR-mediated mTORC1 signaling, underscoring their potential to revolutionize cancer treatment and the management of related pathophysiological conditions.

17 July 2025 in bioRxiv
Verified
Preprint
Open access
VPVikrant Piprode
Vikrant Piprode
SBShubhanath Behera
Shubhanath Behera
JKJuilee Karhade
Juilee Karhade
GPGarima Pandey
Garima Pandey
APArpita Prasad
Arpita Prasad
MWMohan R. Wani
Mohan R. Wani
Postmenopausal osteoporosis (PMO), a silent disorder caused due to estrogen deficiency, is characterized by loss of bone mass and low bone mineral density. Despite advancements in treatment, current medications often fail to fully restore bone integrity and prevent fragility fractures in the osteoporotic individuals. Thus, there is a high demand of novel therapeutic modalities in dealing with osteoporosis. Interleukin-3 (IL-3), a cytokine secreted by activated T cells, emerges as a promising therapeutic candidate. The dual role of IL-3 in inhibiting osteoclast differentiation and promoting osteoblast differentiation, offers protection against bone and joint degeneration in arthritic mice. However, its role in osteoporosis is not yet delineated. Therefore, our investigation focuses on elucidating the role of IL-3 in PMO, employing both prophylactic and therapeutic strategies in ovariectomized mice, mimicking human PMO. In our study, at the onset of osteoporosis, IL-3 treatment effectively preserved trabecular bone architecture and enhanced bone mineral density in OVX mice, particularly notable in therapeutic interventions where fully developed osteoporosis was addressed. Notably, in preventive measures, IL-3 inhibited osteoclast differentiation, thereby suppressing bone resorption, while in therapeutic approaches, it enhanced osteoblast differentiation, promoting bone formation. Irrespective of gender specific, microCT analysis of IL-3 -/- (KO) mice showed reduced trabecular bone development compared to its respective wild type (WT) mice, highlighting essential role of IL-3 in skeletal integrity. Moreover, IL-3 increased Treg cells population while inhibiting B cell lymphopoiesis in ovariectomized mice with no adverse effects on hematopoiesis or vital organs. In conclusion, our findings collectively underscore the potential of IL-3 as a novel therapy for PMO, offering insights into its mechanisms of action and clinical applications. One Sentence Summary: IL-3 has a dual action on bone: anti-osteoclastic and pro-osteoblastic in OVX mice, thus can be a novel therapeutic drug in treating postmenopausal osteoporosis.

22 August 2026 in Cells
Verified
Journal Article
Open access
PDF file
SVSohrab Virk
Sohrab Virk
VSVeeraj Shah
Veeraj Shah
VPVikrant Piprode
Vikrant Piprode
CKClaire Marie Kemp
Claire Marie Kemp
HAHarshith Alluri
Harshith Alluri
CDChitra L Dahia
Chitra L Dahia
Sonic hedgehog (SHH) expression by nucleus pulposus (NP) cells is important for intervertebral disc development and maintenance. The lumbosacral disc, the most immobile region of the spine, lies adjacent to the sacrum and is most vulnerable to degeneration. We hypothesized that a lack of mobility represses SHH expression by NP cells, leading to degenerative changes in the intervertebral disc. To test this hypothesis, we employed a Shh-LacZ reporter mouse and a tail-loop surgical model of constant compression and immobility. Using a comprehensive level-by-level analysis, we first determined the coccygeal level most affected by geometric and histopathological changes. We next determined the effects of constant compression and immobility on the subset of SHH-expressing cells compared with sham controls. Multiplex qPCR analysis validated a decline in Shh and its target Gli1 expression by NP cells in the tail-looped discs that was associated with an increase in Piezo1 expression compared to sham controls. In summary, the findings support a model in which restricted mobility and sustained compression in lumbosacral discs accelerate pathology by prematurely silencing developmental signaling programs, such as SHH, required for NP homeostasis.